Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.

Inclusion Criteria: * Histologically confirmed diagnosis of RCC with clear cell component * Measurable disease * Treated with up to 6 prior systemic therapies for advanced/recurrent disease or have become intolerant to a systemic therapy * Subjects with treated brain metastases must be without magnetic resonance imaging (MRI) evidence of progression for at least 8 weeks and off steroids for at least 4 weeks to be eligible * At least 28 days since the last chemotherapy * At least 28 days before the first dose of MDX 1411 since any major surgery * ECOG performance status 0-2 * No known positivity for human immunodeficiency virus (HIV), Hep B or C Exclusion Criteria: * Previous treatment with any other anti-CD70 antibody * Active infection requiring i.v systemic therapy within 28 days before first dose * Evidence of bleeding diathesis or coagulopathy * Active autoimmune disease requiring immunosuppressive therapy * Known current drug or alcohol abuse * Any underlying medical condition which will make the administration of MDX 1411 hazardous * Psychiatric illness or social situation that would preclude study compliance